相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial
S. L. Samson et al.
DIABETOLOGIA (2011)
Randomized Controlled Trial Testing the Effects of Weight Loss on Nonalcoholic Steatohepatitis
Kittichai Promrat et al.
HEPATOLOGY (2010)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Serum Dipeptidyl Peptidase-4 Activity in Insulin Resistant Patients with Non-Alcoholic Fatty Liver Disease: A Novel Liver Disease Biomarker
Gabor Firneisz et al.
PLOS ONE (2010)
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre et al.
DIABETIC MEDICINE (2009)
Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis
Bogdan Balas et al.
JOURNAL OF HEPATOLOGY (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents?
CHS McIntosh et al.
REGULATORY PEPTIDES (2005)
A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease
E Bugianesi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2005)
Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease
F Angelico et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity
JD Browning et al.
HEPATOLOGY (2004)
Nonalcoholic Fatty Liver Disease: A Review of Current Understanding and Future Impact
Michael Charlton
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss
JB Dixon et al.
HEPATOLOGY (2004)
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C
CT Wai et al.
HEPATOLOGY (2003)
Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review
RT Wang et al.
AMERICAN JOURNAL OF MEDICINE (2003)
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients
Y Miyazaki et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes:: a parallel-group study
M Zander et al.
LANCET (2002)
The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men
H Agerso et al.
DIABETOLOGIA (2002)
A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans
C Verdich et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Nonalcoholic fatty liver disease - A feature of the metabolic syndrome
G Marchesini et al.
DIABETES (2001)
分享论文
